Ning Xianling, Qi Hailong, Li Ridong, Jin Yan, McNutt Michael A, Yin Yuxin
a Institute of Systems Biomedicine, School of Basic Medical Sciences , Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center , Beijing , China.
b Department of Pharmacology, School of Basic Medical Sciences , Peking University Health Science Center , Beijing , China.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):126-129. doi: 10.1080/14756366.2017.1404591.
The M2 isoform of pyruvate kinase (PKM2) is a potential antitumor therapeutic target. In this study, we designed and synthesised a series of 2, 3-didithiocarbamate substituted naphthoquinones as PKM2 inhibitors based on the lead compound 3k that we previously reported. Among them, compound 3f (IC = 1.05 ± 0.17 µM) and 3h (IC = 0.96 ± 0.18 µM) exhibited potent inhibition of PKM2, and their inhibitory activities are superior to compound 3k (IC = 2.95 ± 0.53 µM) and the known PKM2 inhibitor shikonin (IC = 8.82 ± 2.62 µM). In addition, we evaluated in vitro antiproliferative effects of target compounds using MTS assay. Most target compounds exhibited dose-dependent cytotoxicity with IC values in nanomolar concentrations against HCT116, MCF7, Hela, H1299 and B16 cells. These small molecule PKM2 inhibitors not only provide candidate compounds for cancer therapy, but also offer a tool to probe the biological effects of PKM2 inhibition on cancer cells.
丙酮酸激酶M2亚型(PKM2)是一个潜在的抗肿瘤治疗靶点。在本研究中,我们基于之前报道的先导化合物3k设计并合成了一系列2,3 - 二硫代氨基甲酸酯取代的萘醌作为PKM2抑制剂。其中,化合物3f(IC = 1.05 ± 0.17 μM)和3h(IC = 0.96 ± 0.18 μM)对PKM2表现出强效抑制作用,它们的抑制活性优于化合物3k(IC = 2.95 ± 0.53 μM)和已知的PKM2抑制剂紫草素(IC = 8.82 ± 2.62 μM)。此外,我们使用MTS法评估了目标化合物的体外抗增殖作用。大多数目标化合物对HCT116、MCF7、Hela、H1299和B16细胞表现出剂量依赖性细胞毒性,IC值处于纳摩尔浓度范围。这些小分子PKM2抑制剂不仅为癌症治疗提供了候选化合物,还为探究PKM2抑制对癌细胞的生物学效应提供了一种工具。